These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 29733378)

  • 1. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
    Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
    Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.
    Paech D; Dreher C; Regnery S; Meissner JE; Goerke S; Windschuh J; Oberhollenzer J; Schultheiss M; Deike-Hofmann K; Bickelhaupt S; Radbruch A; Zaiss M; Unterberg A; Wick W; Bendszus M; Bachert P; Ladd ME; Schlemmer HP
    Eur Radiol; 2019 Sep; 29(9):4957-4967. PubMed ID: 30809720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
    Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
    Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
    Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
    J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial for "Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma".
    Salihoğlu AK; Booth TC
    J Magn Reson Imaging; 2023 Sep; 58(3):739-740. PubMed ID: 36594487
    [No Abstract]   [Full Text] [Related]  

  • 8. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.
    Zhou M; Niu C; Jia L; He H
    Medicine (Baltimore); 2019 Dec; 98(50):e18194. PubMed ID: 31852075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
    Lu J; Li X; Li H
    Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
    Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
    Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
    Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
    Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV° gliomas is dependent on the anatomic location.
    Dreher C; Oberhollenzer J; Meissner JE; Windschuh J; Schuenke P; Regnery S; Sahm F; Bickelhaupt S; Bendszus M; Wick W; Unterberg A; Zaiss M; Bachert P; Ladd ME; Schlemmer HP; Radbruch A; Paech D
    J Magn Reson Imaging; 2019 Mar; 49(3):777-785. PubMed ID: 30133046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
    Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
    Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.